WO2012166056A1 - Procédé utilisant des fragments pour la conception d'inhibiteurs par spectrométrie de masse couplée aux échanges d'hydrogène d'amide/deutérium - Google Patents

Procédé utilisant des fragments pour la conception d'inhibiteurs par spectrométrie de masse couplée aux échanges d'hydrogène d'amide/deutérium Download PDF

Info

Publication number
WO2012166056A1
WO2012166056A1 PCT/SG2012/000196 SG2012000196W WO2012166056A1 WO 2012166056 A1 WO2012166056 A1 WO 2012166056A1 SG 2012000196 W SG2012000196 W SG 2012000196W WO 2012166056 A1 WO2012166056 A1 WO 2012166056A1
Authority
WO
WIPO (PCT)
Prior art keywords
small molecule
target protein
fragments
interest
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SG2012/000196
Other languages
English (en)
Inventor
Ganesh Srinivasan ANAND
Srinath KRISHNAMURTHY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University of Singapore
Original Assignee
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University of Singapore filed Critical National University of Singapore
Publication of WO2012166056A1 publication Critical patent/WO2012166056A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry

Definitions

  • Fragment-based drug discovery is a new field that is based on identifying small chemical fragments and then growing them or combining them to produce molecules for exploration in therapeutic applications.
  • FBDD Fragment-based drug discovery
  • KQ dissociation constant
  • FBDD screens a limited number of molecules which bind with very low affinities (Dissociation constant (KQ)) ranging from high ⁇ to mM) to the target protein.
  • KQ dissociation constant
  • KQ dissociation constant
  • the inherent drawback of using low affinity binding fragments is the inadequacy of effective screening methods.
  • the limitations of current assays include poor dynamic range to enable screening of low affinity binders, economy of protein and fragment samples, throughput and turnaround time of analysis.
  • the present invention pertains to methods of screening small molecule fragments having a low binding affinity to a target protein, to identify fragments of interest, as well as to methods for identifying a binding site of interest within a target protein.
  • the methods include either a) generating a deuterium exchange kinetic profile of the target protein in an unliganded state and in a ligand bound state in the presence of a natural ligand/substrate or substrate analog, and determining an optimal labeling time (TL) of deuterium exchange by measuring the relative deuteration exchange values for the unliganded state and for the ligand bound state determined in step (a) for peptide regions within the protein which show a maximum difference in relative deuteration exchange values between the unliganded state and the ligand bound state (the "test peptides"); or (b) utilizing a standardized chart of T L for the target protein.
  • Small molecule fragments having a low binding affinity are used.
  • the small molecules can be, for example, peptides, organic molecules, and/or any other ligand capable of binding to the target protein.
  • Such molecules can have a binding affinity, for example, of under 10 mM (e.g., 100 ⁇ to 1 niM).
  • the small molecule fragments are incubated with the target protein (e.g., in solution in which the concentration of the target protein is 10-50 ⁇ ), for the period of time T L , and then a Ligand-Peptide Binding Index (LPBI) value is assigned for each of the test peptides as a ratio of change in number of deuterons (D) exchanged upon fragment binding to the number of heavy atoms (HA) of the small molecule fragments (AD/HA). In a preferred embodiment, the ratio is 2000:1.
  • a composite LPBI value is formed for each of the small molecule fragments by summing the individual LBPI values of step (d) for the test peptides; and at least one small molecule fragment with a composite LPBI value of interest is identified.
  • Such small molecule fragments of interest can be used, for example, as building blocks for a drug candidate. Furthermore, if more than one fragment is identified, they can be assembled together, such as by a combinatorial chemistry approach. In addition, identification of a small molecule fragment of interest allows identification of its binding site in the target protein, and thereby identifies a binding site of interest (e.g., a catalytic active site, an allosteric site) within the target protein.
  • a binding site of interest e.g., a catalytic active site, an allosteric site
  • the methods of the invention offer significant advantages over conventional approaches for FBDD, including small size of protein samples, enhanced throughput, detailed information on conformational dynamics and allostery in solution. It also offers a strategy for combining binding kinetics with binding site analysis-something that is very inefficiently and inadequately addressed by current methods.
  • Fragment-based drug design is a process of linking or expanding multiple fragments to generate high-affinity binders.
  • Fig. 1 depicts the fragments and natural inhibitors that were tested in pilot studies for binding to the N-terminal fragment domain of Hsp90.
  • the top box are two high affinity natural inhibitors- radicicol and a geldanamycin derivative (17 A AG), which bind with Dissociation constants of 19 and 33 nM, the structures and molecular weights are from the references listed on the slide.
  • the bottom box are three fragments that were tested for binding with the N-terminal fragment domain of Hsp90 by amide hydrogen/deuterium exchange- EA1, EA4 and aminopyrimidine (AMP).
  • Fig. 2 depicts a Butterfly Plot comparison of amide hydrogen/deuterium exchange for the free, unbound and radicicol-bound samples of the N-terminal domain of Hsp90 protein, after 1 min deuterium exchange.
  • Fig. 3 similarly depicts a Butterfly Plot comparison of amide
  • Fig. 4 depicts a modified Butterfly Plot displaying the results for the fragment EA4 following 1 min deuterium exchange.
  • the regions showing decreased exchange upon EA4 binding are a subset of those seen upon radicicol binding.
  • Fig. 5 depicts a modified Butterfly Plot displaying the results for the fragment EA4 following 10 min deuterium exchange. Magnitude of differences are smaller after 10 min than at 1 min (Fig. 4).
  • Fig. 6 depicts the structure of the radicicol-bound N-terminal fragment domain of Hsp90, highlighting a particular region that shows differential exchange with certain fragments and natural inhibitors highlighted in red ( residues 126-141).
  • residues 126-141) On the right panel is overlaid the isotopic envelope from the mass spectrometer., highlighting how the pattern or 'signature' resembles radicicol ( in dashed boxes).
  • Fig 7 is a schematic illustration of a computer network in which
  • embodiments may be deployed.
  • Fig. 8 is a block diagram of a computer node in the network of Fig 7.
  • This invention pertains to a novel application of amide hydrogen/deuterium exchange mass spectrometry in screening low binding affinity small molecule fragments that bind target proteins, for use, for example, in fragment-based drug discovery (e.g., for generating building blocks of a drug candidate)
  • this invention allows mapping of binding sites of interest within target proteins,-including catalytic active sites and allosteric sites, through identification of small molecule fragments that bind to the target protein.
  • Such small molecule fragments can serve as building blocks for compounds of interest for effective drug design, such as through combinatorial chemistry approaches.
  • This invention describes a novel application of amide deuterium exchange mass spectrometry as a screening tool for Fragment Based Drug Discovery (FBDD).
  • FBDD Fragment Based Drug Discovery
  • the present invention provides a method for screening low affinity fragments that bind to a target protein, combining ligand binding with structural and
  • This invention gives a new faster and powerful method for screening low affinity fragments that bind to a target protein with binding, structural and functional information as an output.
  • AMIDE HYDROGEN/DEUTERIUM EXCHANGE MASS SPECTROMETRY AMIDE HXMS
  • Amide HXMS is a powerful technique that allows measurement of deuterium exchange at backbone amide hydrogens in proteins (reviewed by Hoofnagle, A.N., Resing, K.A. and Ahn, N.G. (2003) Protein analysis by hydrogen exchange mass spectrometry. Annu. Rev. Biophys. Biomol. Struct. 32, 1-25.).
  • Monitoring the exchange provides important insights into protein structure and dynamics in solution.
  • the method involves dilution of protein samples of interest in deuterated buffer, which is the aqueous buffer prepared in Deuterium oxide (D 2 0).
  • D 2 0 Deuterium oxide
  • the extent of exchange varies across the molecule and is dependent both on solvent accessibility and dynamics of the protein backbone at that region. This pH- dependent process is slowed down several orders of magnitude at pH 2.5.
  • pH and temperature of the samples are rapidly adjusted to pH ⁇ 2.5 and 0 °C to 'quench' the deuterium exchange reaction.
  • Samples are then subjected to complete proteolytic digestion with the protease pepsin and analyzed by mass spectrometry. The extent of deuterium exchange is reflected in the alteration of distribution of the isotopic envelopes of the individual fragment peptides. Average deuterons exchanged in each fragment peptide are calculated from the mass spectral envelope by publically available and commercial centroid determination software.
  • small molecule fragment refers to a small (e.g., less than or equal to 300 kDa in size, such as less than or equal to 300 kDa; less than or equal to 250 kDa; less than or equal to 200 kDa; less than or equal to 150 kDa; and less than or equal to 100 kDa) molecule having a KD ranging from low ⁇ (e.g., 5 ⁇ ; 10 ⁇ , 50 ⁇ ; 100 ⁇ ) to low mM (e.g., 10 mM; 5 mM; 1 mM; or other) .
  • low ⁇ e.g., 5 ⁇ ; 10 ⁇ , 50 ⁇ ; 100 ⁇
  • low mM e.g., 10 mM; 5 mM; 1 mM; or other
  • the small molecules can be, for example, peptides, organic molecules, short nucleic acid sequences (e.g., DNA sequences, RNA sequences, etc.), and/or any other ligand capable of binding to the targeted protein.
  • the "target protein” can be any protein of interest; for example, representative target proteins include, for example, biological enzymes or membrane proteins such as receptors (e.g., receptor proteins that are anchored in membranes).
  • a group of small molecule fragments of interest to be used in the methods of the invention can be identified through conventional fragment screens.
  • conventional fragment screens are initiated with a relatively large population of fragments (e.g., 2000 fragments or more) in their library.
  • the fragments are screened using preliminary screening methods specifically suited to the target protein of interest to identify a panel of fragments that bind to that protein, such as calorimetry-based binding assays.
  • preliminary screening methods specifically suited to the target protein of interest to identify a panel of fragments that bind to that protein, such as calorimetry-based binding assays.
  • a group of small molecule fragments of interest is selected for the methods of the invention using Amide
  • the group of small molecule fragments of interest can be, for example, 1000 or fewer fragments, or 500 or fewer fragments; in a preferred embodiment, the group is 200 or fewer, such as 100 or fewer, fragments.
  • a first step of the invention is to obtain deuterium exchange kinetic profiles of the target protein in the unliganded state and in a ligand bound state (i.e., in the presence of a natural ligand/substrate or substrate analog) over time.
  • the time series can range from 10 or fewer seconds, to 3 hours.
  • a typical starting time series is 30 seconds, 1 minute, 2 minutes, 5 minutes, and 10 minutes.
  • This step identifies the timepoint that is the most optimal for fragment screening.
  • the timepoint of deuterium exchange where the greatest magnitude changes upon binding of the natural ligand/substrate or substrate analog is selected as the labeling time (TL) for ligand fragment screening.
  • This optimal labeling time is determined by measuring the relative deuteration exchange values for the unliganded state and the native ligand bound state quantitated at each timepoint.
  • the labeling time (TL) can be obtained from a standardized chart of TL values for the target protein, that can be generated using routine methods such as those described above.
  • the hydrogen/deuterium exchange reactions are carried out in triplicate, or more. For a difference in deuterium exchange to be considered significant, guidelines are employed: a difference in exchange between one state and another should be greater than the sum of the standard deviations in deuterium exchange for the two states.
  • peptide regions within the target protein are explored.
  • the peptide regions include, for example, a non-redundant set of peptides from various regions of the target protein, such as set from regions within one or more ligand binding pocket(s).
  • a high resolution x-ray crystal structure of the ligand-bound protein can be used, for example, to identify the ligand binding pocket and the peptides within that region.
  • a set of peptides from various regions of the target protein such as set from regions within one or more ligand binding pocket(s).
  • a high resolution x-ray crystal structure of the ligand-bound protein can be used, for example, to identify the ligand binding pocket and the peptides within that region.
  • nonoverlapping peptides based on the sequence of the target protein can also be used. Typical regions range from about 5 to 20 amino acids in length, inclusive.
  • the peptide regions that show the maximum difference in relative deuteration values between the unliganded state and for the ligand bound state (referred to herein as "test peptides") are identified. For example, if the peptides are ranked in descending order of shift in relative deuterium exchange, the top non-redundant and
  • nonoverlapping peptides e.g., at least 10 or more, such as 20 or more or 30 or more
  • the number can be varied, depending on the size of the protein; generally, larger proteins will have larger groups of peptides.
  • the small molecule fragments are incubated with the target protein. They are incubated at a molar excess of fragments to ensure saturation of the protein (A ratio of 2000: 1 for fragment to target protein, such as at concentrations of approximately 10- 50 uM, would facilitate saturation of a fragment ligand that binds with low mM affinity). They are incubated for a time period (duration) equal to TL determined as described above.
  • a Ligand-Peptide Binding Index (LPBI) value is assigned for each of the 'test peptides'. This value is the ratio of change in number of deuterons exchanged upon fragment binding to the number of heavy atoms (AD/HA).
  • Each ligand fragment thus has assigned a LBPI score for each of the test peptides.
  • the LBPI scores for each test peptide is summed up to yield a composite LBPI value for that small molecule fragment.
  • the LBPI scores can be tabulated for each peptide, and then the LBPI scores of all the ligands can be ranked in descending order.
  • Small molecule fragments with composite LPBI values of interest can then be identified. For example, all fragment ligand Composite LBPI values can be ranked in order, and the top value or values can be identified as the value(s) for which the small molecule fragment(s) are of interest .
  • a fragment "of interest,” as used herein, refers to a fragment that has the desired characteristic(s) (e.g., a particular LPBI value). For example, such fragments may be useful for generating building blocks, e.g., of a drug candidate. For example, the fragments of interest represent the 'lead' molecules targeting a therapeutic protein of interest. If desired, more than one fragment can be selected (identified) as being a small molecule fragment of interest. Multiple (e.g., 2 or more) small molecule fragments of interest can be combined to generate drug candidates. In certain embodiments, a
  • combinatorial chemistry approach can be used to assemble the small molecule fragments of interest. For example, chemistries of 'lead' molecules affecting distinct sets of peptides on the target can then be combined to yield hybrids with higher binding and improved specificity. If desired, validation of combinatorial chemistry can again be achieved through repeating the steps described above. An iterative approach can verify the utility of such molecules as drug candidates (e.g., for biological or therapeutic drug testing).
  • the methods described above can be used to identify binding sites of interest within a target protein.
  • a small molecule fragment with a composite LPBI value of interest can be identified, as described above; such a small molecule fragment binds to the target protein at a particular site (its binding site, which can be, for example, a particular peptide region of the target protein); this site (peptide region) is identified as a binding site of interest within the target protein.
  • the binding site of interest can be a catalytic active site, or an allosteric site.
  • Some of the advantages of the methods described herein include highly improved throughput, robustness, conformational dynamics information in solution, and minimalized workflow timeframe.
  • the methods provide means for identifying small molecule fragments of interest that interact with a target protein, thereby facilitating creation of drug candidates or other relevant molecules such as through use of the fragments of interest as building blocks for candidate molecules; the methods also provide binding site analysis and identification of relevant binding sites of interest within a target protein. All measurements take into account the inherent dynamics of the target proteins. Importantly, the methods allow for narrowing down the possible interaction sites on the target protein.
  • the present methods allow defining of the binding site, such as by looking at a structure of a target and identifying the regions that show decreased or increased exchange. Furthermore, the methods provide clear mapping details to examine induced conformational change and allostery. The methods work in solution, require minimal amounts of protein and ligands, and do not require immobilization (e.g., on a chip), allowing easy adaptation to investigate membrane proteins.
  • the N-terminal domain of Hsp90 from yeast was explored using the methods described herein.
  • the N-terminal domain binds to the high affinity natural inhibitor radicicol, as determined by X-ray crystallography (Huth et al. (2007), Chem. Biol. Drug Des. 70:1-12; Roe et al. (1999), J. Med. Chem. 42:260-266;
  • PDB ID 1BGQ Protein Data Bank
  • This test protein that used to establish the utility of amide hydrogen/deuterium exchange mass spectrometry for fragment- based drug design. Results are shown in the figures.
  • the mass spectrometry data in the figures have been collected on a Synapt High Definition Mass spectrometry from Waters Corporation, Milford, MA and the results are displayed using Waters Commercial software, DynamX (v 1.0) and HDX Browser (development pre-release software whose features were incorporated into the commercial DynamX software).
  • Fig. 1 depicts the fragments and natural inhibitors that were tested in pilot studies for binding to the N-terminal fragment domain of Hsp90.
  • the top box are two high affinity natural inhibitors- radicicol and a geldanamycin derivative (17 AAG), which bind with Dissociation constants of 19 and 33 nM, the structures and molecular weights are from the references listed on the slide.
  • the bottom box are three fragments that were tested for binding with the N-terminal fragment domain of Hsp90 by amide hydrogen/deuterium exchange- EA1, EA4 and aminopyrimidine (AMP).
  • Fig. 2 depicts a comparison of amide hydrogen/deuterium exchange for the free, unbound and radicicol-bound samples of the N-terminal domain of Hsp90 protein.
  • the plot is a Butterfly Plot and generated by proprietary commercial software- DynamX ( v. 1.0)( Waters Corporation, Milford, MATM).
  • all the pepsin digest fragments of the target protein are listed from the N- to C-terminus ( X-axis).
  • the distribution of peptides is not to scale, as it is a function of pepsin's specificity of cleavage at certain sites on the target protein.
  • the gray plot is the exchange ( after 1 min deuterium exchange) for free unliganded Hsp90 and the black plot is that with radicicol bound.
  • 'Bubbles' indicate regions where the radicicol- bound Hsp90 shows lower deuterium exchange compared to the free protein.
  • Fig. 3 similarly depicts a comparison of amide hydrogen/deuterium exchange for the free, unbound and radicicol-bound samples, except after 10 min deuterium exchange.
  • Fig. 4 depicts a modified Butterfly Plot displaying the results for the fragment EA4 following 1 min deuterium exchange. The regions showing decreased exchange upon EA4 binding are a subset of those seen upon radicicol binding.
  • Fig. 5 depicts a modified Butterfly Plot displaying the results for the fragment EA4 following 10 min deuterium exchange. Magnitude of differences are smaller after 10 min than at 1 min.
  • Fig. 6 depicts the structure of the radicicol-bound N-terminal fragment domain of Hsp90, highlighting a particular region that shows differential exchange with certain fragments and natural inhibitors highlighted in red ( residues 126-141).
  • On the right panel is overlaid the isotopic envelope from the mass spectrometer., highlighting how the pattern or 'signature' resembles radicicol ( in dashed boxes).
  • This qualitative assessment shows that the similarity is not seen with the other combinations of fragments and inhibitors.
  • amide hydrogen/deuterium exchange is highly sensitive to pick up differences in interactions between two weak-binder fragments ( EA1 and EA4). This
  • HDX browserTM a feature that is part of commercial proprietary amide hydrogen/deuterium exchange software DynamXTM from Waters Corporation, Milford, MA.
  • the first step is to carry out an HDXMS time-series experiment with the target protein and high affinity ligand/analog. Suggested deuterium exchange labeling times range from 10-30 seconds and longer (a typical starting time series is 30 seconds, 1 minute, 2 minutes, 5 minutes and 10 minutes*). From the HDXMS experiment, a single labeling time is selected as a standard labeling time for the entire fragment library. The labeling time selected is the shortest time point that shows 75% or greater deuterium exchange seen after 10 minutes of deuterium exchange for at least 3 pepsin digest fragment peptides** . A set of peptides
  • n (number: n) are chosen which show the maximum changes in deuterium exchange upon ligand binding.
  • This set of peptides should be a non-redundant set from various regions in the ligand binding pocket, if a high resolution X-ray crystal structure of the ligand-bound protein is available. If a structure is not available, then a set of nonoverlapping peptides, on the basis of primary sequence are chosen.
  • the fragment screen is carried out for the entire set of fragments. Only the peptides that are in the peptide set (n) are selected for analysis. The deuterium exchange is quantified for each fragment, and the Binding efficiency factor for each fragment is calculated from the following formula. This will be a finite value and based on the summation of all the peptides in the test set.
  • the binding efficiency factor is also applied for the high affinity natural ligand as
  • Fragment rank factor BEF of Natural Ligand/ analogue
  • This value can range from 0 to above 1 for fragments that are more efficient than the high affinity ligand. Fragments will be ranked according to their Fragment rank factor.
  • this value can be monitored to develop high affinity inhibitors. Improvements in inhibitor design can thus be tracked with every iterative step.
  • this time series captures deuterium exchange at fast exchanging amides. For some proteins, this time series may need to be extended to longer labeling times.
  • the Binding efficiency factor equation is modified to the following equation
  • Binding efficiency f actor , n MW
  • AD - Deuterium ions exchanged in the unliganded state- Deuterium ions exchanged in presence of fragment 'i'
  • Fragments are ranked according to their absolute BEF to determine which fragments can be considered for molecule linking and expansion in iterative FBDD.
  • Embodiments may employ a computer-based machine or digital processor configured to implement the forgoing calculations.
  • Figs 7 and 8 show a computer network in which computer embodiments may be deployed.
  • Figure 7 illustrates a computer network or similar digital processing environment in which the present invention may be implemented.
  • Client computer(s)/devices 50 and server computer(s) 60 provide processing, storage, and input/output devices executing application programs and the like.
  • Client computer(s)/devices 50 can also be linked through communications network 70 to other computing devices, including other client devices/processes 50 and server computer(s) 60.
  • Communications network 70 can be part of a remote access network, a global network (e.g., the Internet), a worldwide collection of computers, Local area or Wide area networks, and gateways that currently use respective protocols (TCP/IP, Bluetooth, etc.) to communicate with one another.
  • a global network e.g., the Internet
  • Other electronic device/computer network architectures are suitable.
  • Fig.8 is a diagram of the internal structure of a computer (e.g., client processor/device 50 or server computers 60) in the computer system of Fig. Na.
  • Each computer 50, 60 contains system bus 79, where a bus is a set of hardware lines used for data transfer among the components of a computer or processing system.
  • Bus 79 is essentially a shared conduit that connects different elements of a computer system (e.g., digital processor, disk storage, memory, input/output ports, network ports, etc.) that enables the transfer of information between the elements.
  • I/O device interface 82 Attached to system bus 79 is I/O device interface 82 for connecting various input and output devices (e.g., keyboard, mouse, displays, printers, speakers, etc.) to the computer 50, 60.
  • Network interface 86 allows the computer to connect to various other devices attached to a network (e.g., network 70 of Fig. Na).
  • Memory 90 provides volatile storage for computer software instructions 92 and data 94 used to implement an embodiment of the present invention (e.g., formula for calculating Binding efficiency factor for a fragment, formula for calculating Fragment rank factor, routine or module for ranking or ordering of fragments and displaying indications of resulting identified small molecule fragments of interest, and supporting code detailed above).
  • Disk storage 95 provides non-volatile storage for computer software instructions 92 and data 94 used to implement an embodiment of the present invention.
  • Central processor unit 84 is also attached to system bus 79 and provides for the execution of computer instructions.
  • CPU 84 may also be referred to as a digital processor.
  • the processor routines 92 and data 94 are a computer program product (generally referenced 92), including a computer readable medium (e.g., a removable storage medium such as one or more DVD-ROM's, CD-ROM's, diskettes, tapes, etc.) that provides at least a portion of the software instructions for the invention system.
  • Computer program product 92 can be installed by any suitable software installation procedure, as is well known in the art.
  • at least a portion of the software instructions may also be downloaded over a cable, communication and/or wireless connection.
  • the invention programs are a computer program propagated signal product 107 embodied on a propagated signal on a propagation medium (e.g., a radio wave, an infrared wave, a laser wave, a sound wave, or an electrical wave propagated over a global network such as the Internet, or other network(s)).
  • a propagation medium e.g., a radio wave, an infrared wave, a laser wave, a sound wave, or an electrical wave propagated over a global network such as the Internet, or other network(s).
  • Such carrier medium or signals provide at least a portion of the software instructions for the present invention routines/program 92.
  • the propagated signal is an analog carrier wave or digital signal carried on the propagated medium.
  • the propagated signal may be a digitized signal propagated over a global network (e.g., the Internet), a telecommunications network, or other network.
  • the propagated signal is a signal that is transmitted over the propagation medium over a period of time, such as the instructions for a software application sent in packets over a network over a period of milliseconds, seconds, minutes, or longer.
  • the computer readable medium of computer program product 92 is a propagation medium that the computer system 50 may receive and read, such as by receiving the propagation medium and identifying a propagated signal embodied in the propagation medium, as described above for computer program propagated signal product.

Landscapes

  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Computing Systems (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Library & Information Science (AREA)
  • Theoretical Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des procédés de criblage de fragments de petites molécules présentant une faible affinité de liaison à l'égard d'une protéine voulue, en vue d'identifier des fragments voulus ou des sites de liaison voulus dans une protéine voulue. Dans ces procédés, des valeurs d'indice de liaison ligand-peptide (LPBI) sont attribuées à des peptides d'essai et des valeurs de LPBI composite sont déterminées, lesdites valeurs permettant d'identifier des fragments de petites molécules présentant une valeur de LPBI composite voulue et de déterminer les sites de liaison pertinents dans la protéine voulue. Les valeurs de LPBI peuvent être produites par ordinateur.
PCT/SG2012/000196 2011-06-02 2012-06-01 Procédé utilisant des fragments pour la conception d'inhibiteurs par spectrométrie de masse couplée aux échanges d'hydrogène d'amide/deutérium Ceased WO2012166056A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161492549P 2011-06-02 2011-06-02
US61/492,549 2011-06-02

Publications (1)

Publication Number Publication Date
WO2012166056A1 true WO2012166056A1 (fr) 2012-12-06

Family

ID=47259630

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2012/000196 Ceased WO2012166056A1 (fr) 2011-06-02 2012-06-01 Procédé utilisant des fragments pour la conception d'inhibiteurs par spectrométrie de masse couplée aux échanges d'hydrogène d'amide/deutérium

Country Status (1)

Country Link
WO (1) WO2012166056A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111239353A (zh) * 2020-01-19 2020-06-05 辉源生物科技（上海）有限公司 一种人源柠檬酸转运蛋白抑制剂化合物的筛选方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016100A1 (fr) * 1998-09-11 2000-03-23 Carta Proteomics, Inc. Procedes d'identification pour residus de point chaud de proteines de liaison et petits composes se liant a ces proteines
WO2006014160A2 (fr) * 2004-07-02 2006-02-09 Exsar Corporation Selection de candidats-medicaments par caracterisation via un profil d'echange d'hydrogene d'une conformation du recepteur induite par ligand

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016100A1 (fr) * 1998-09-11 2000-03-23 Carta Proteomics, Inc. Procedes d'identification pour residus de point chaud de proteines de liaison et petits composes se liant a ces proteines
WO2006014160A2 (fr) * 2004-07-02 2006-02-09 Exsar Corporation Selection de candidats-medicaments par caracterisation via un profil d'echange d'hydrogene d'une conformation du recepteur induite par ligand

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARR ET AL.: "Fragment-based lead discovery: leads by design", DRUG DISCOVERY TODAY, vol. 10, no. 14, 2005, pages 987 - 992 *
CHALMERS ET AL.: "Differential hydrogen/deuterium exchange mass spectrometry analysis of protein-ligand interactions", EXPERT REVIEW OF PROTEOMICS, vol. 8, no. 1, February 2011 (2011-02-01), pages 43 - 59 *
CONGREVE ET AL.: "Recent Developments in Fragment-Based Drug Discovery", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 13, 2008, pages 3661 - 3680 *
HAMURO ET AL.: "Protein-Targeting Drug Discovery Guided by Hydrogen/Deuterium Exchange Mass Spectrometry (DXMS)", MASS SPECTROMETRY IN MEDICINAL CHEMISTRY: APPLICATIONS IN DRUG DISCOVERY, 2007, GERMANY, pages 377 - 398 *
WANG ET AL.: "Probing protein structure and dynamics by hydrogen exchange-mass spectrometry", CURRENT PROTOCOLS IN PROTEIN SCIENCE, 2002, pages 17.6.1 - 17.6.18 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111239353A (zh) * 2020-01-19 2020-06-05 辉源生物科技（上海）有限公司 一种人源柠檬酸转运蛋白抑制剂化合物的筛选方法

Similar Documents

Publication Publication Date Title
Alibay et al. Evaluating the use of absolute binding free energy in the fragment optimisation process
Wilson et al. Integrating structure-based and ligand-based approaches for computational drug design
Merz Jr Limits of free energy computation for protein− ligand interactions
Hu et al. LS-align: an atom-level, flexible ligand structural alignment algorithm for high-throughput virtual screening
Feng et al. Absolute binding free energy calculations improve enrichment of actives in virtual compound screening
Liu et al. The origin of the cooperativity in the streptavidin-biotin system: A computational investigation through molecular dynamics simulations
Wu et al. Elucidation of protein–ligand interactions by multiple trajectory analysis methods
Wang et al. Ranking ligand binding affinities with avidin: a molecular dynamics‐based interaction energy study
Wagner et al. Continuous evaluation of ligand protein predictions: a weekly community challenge for drug docking
Rossato et al. AcquaAlta: a directional approach to the solvation of ligand–protein complexes
White et al. Bioinformatics strategies for proteomic profiling
Biesiada et al. Survey of public domain software for docking simulations and virtual screening
Cui et al. Beyond static structures: protein dynamic conformations modeling in the post-AlphaFold era
Wang et al. Identification of drug binding sites and action mechanisms with molecular dynamics simulations
Sampson et al. Robust prediction of relative binding energies for protein–protein complex mutations using free energy perturbation calculations
Sriramulu et al. Effect of molecular properties of the protein-ligand complex on the prediction accuracy of AutoDock
Callil-Soares et al. Effect of preprocessing and simulation parameters on the performance of molecular docking studies
Li et al. Advances in structure-based allosteric drug design
Heo et al. GalaxyWater-wKGB: prediction of water positions on protein structure using wKGB statistical potential
Retra et al. Surface plasmon resonance biosensor analysis as a useful tool in FBDD
Poole et al. Accelerating fragment-based drug discovery using grand canonical nonequilibrium candidate Monte Carlo
Krishnamurthy et al. The evolving role of hydrogen/deuterium exchange mass spectrometry in early-stage drug discovery
Urbina et al. Rationalizing protein–ligand interactions via the effective fragment potential method and structural data from classical molecular dynamics
Prates et al. Predicting receptor-ligand pairing preferences in plant-microbe interfaces via molecular dynamics and machine learning
Walia et al. Sequence-based prediction of RNA-binding residues in proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12792783

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12792783

Country of ref document: EP

Kind code of ref document: A1